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Tietyt verenpainelääkkeet, kuten ATR-salpaajat sekä ACE-estäjät, on yhdistetty parempaan 
ennusteeseen eturauhassyöpäpotilailla. Me tutkimme verenpainelääkkeiden ja 
eturauhassyöpäpotilaiden kuolleisuuden välistä yhteyttä sekä hormonihoidon aloituksen riskiä 
suomalaisilla prostatektomiapotilailla. 
Aineistonamme oli 14 422 eturauhassyöpäpotilaan aineisto Suomen Syöpärekisteristä. Laskimme 
Cox regressiolla riskisuhteet (HR:t) ja 95 % luottamusvälit eturauhassyöpäkuolemille ja 
hormonihoidon aloituksen riskille. Vakioimme analyyseissä iän, kasvaimen levinneisyyden ja 
statiinien käytön sekä lisäsimme analyysiin Charlson comorbidity indeksin.  
Verenpainelääkkeiden käyttö oli yhteydessä kasvaneeseen eturauhassyöpäkuolleisuuteen 
pitkäaikaisseurannassa. Ennen syöpädiagnoosia käytetyt ATR-salpaajat pienensivät 
syöpäkuoleman riskiä (HR: 0.43, 95% CI:0.26-0.72). Samanlaista riskin alenemaa ei havaittu millään 
muulla verenpainelääkeryhmällä. Myös diagnoosin jälkeen käytetyt ATR-salpaajat pienensivät 
eturauhassyöpäkuoleman riskiä (HR: 0.60, 95% CI 0.37-0.97). ATR-salpaajat myös pienensivät 
hormonihoidon aloituksen riskiä (HR: 0.81 CI:0.71-0.92). 
ATR-salpaajien käyttäjät poikkesivat muista potilaista, sillä eturauhassyöpäkuolleisuus oli heillä 
pienempi ja heille aloitettiin harvemmin hormonihoito. ATR-salpaajat ovat lupaava lääkeryhmä, 
jota voisi hyödyntää eturauhassyövän hoidossa, mutta lisää tutkimusta tarvitaan mekanismin 
selvittämiseksi. 
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityChek-ohjelmalla Tampereen 
yliopiston laatujärjestelmän mukaisesti. 
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Novelty and Impact 
Antihypertensive drugs are a very common drug group and in our study they are associated with 
worse prostate cancer survival after radical prostatectomy. Use of antihypertensive drugs also 
may also increase risk of starting androgen-deprivation therapy. In contrast use of ATR-blockers 
may be associated with lower risk of prostate cancer death as well as lower risk of starting 
androgen-deprivation therapy.  
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1 ABSTRACT 
Antihypertensive (anti-HT) drugs targeting renin-angiotensin-aldosterone (RAA)- system have been 
associated with improved prostate cancer (PCa)-specific survival. Challenge is that often multiple 
drugs are used simultaneously. We evaluated the association between use of anti-HT drugs and 
PCa survival among 14,422 surgically treated Finnish PCa patients. Information on drug purchases 
was obtained from a national prescription database. We used Cox regression to calculate hazard 
ratios (HRs) and 95% confidence intervals (95% CIs) for risk of PCa death and initiation of androgen 
deprivation therapy (ADT) with adjustment for age, tumor extent, use of statins and for Charlson 
Comorbidity Index. Angiotensin-converting enzyme (ACE)- inhibitors, angiotensin- receptor (ATR)-
blockers, diuretics, calcium -channel blockers, beta-blockers and other anti-HT drugs were 
analyzed as separate time-dependent variable to model simultaneous use. Overall anti-HT drugs 
were associated with an increased risk of PCa death. Conversarily use of ATR-blockers was 
associated with decreased risk of PCa death (HR: 0.43, 95% CI: 0.26-0.72 and HR: 0.60, 95% CI 
0.37-0.97 for pre- and post-diagnostic use). Similar risk decrease was not observed in other drug 
groups. Anti-HT drugs were also associated with an increased risk of starting ADT, with the 
exception of ATR -blockers (HR: 0.81 CI:0.71-0.92). ATR- blockers differ from other anti-HT drugs as 
the survival is better in users of this drug group. The result partly supports the role of RAA system 
in PCa progression. Nevertheless, the risk decrease was not observed in ACE-inhibitor users. 
Further research is needed to elucidate the molecular mechanism for the potential anticancer 
effect of ATR- blockers. 
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2 INTRODUCTION 
Prostate cancer is the most common cancer among men in the Western countries. It causes great 
losses in terms of health- care expenditure and life-years. Nevertheless, etiology of the disease is 
poorly understood.  
It has been suggested that hypertension, by itself or as part of metabolic syndrome, may be a 
prostate cancer risk factor [1-4]. Furthermore, other factors that associate with hypertension, such 
as elevated heart rate and obesity, may also be associated with prostate cancer risk.[5,6]  
Although hypertension is a putative prostate cancer risk factor, it is unclear whether use of 
antihypertensive drugs might reduce the risk or improve the prognosis. According to some studies 
antihypertensive medication can increase the risk of PCa diagnosis [7]. Some classes of 
antihypertensive drugs, such as angiotensin-receptor blockers and ACE-inhibitors have been 
associated to better PCa survival and better prognosis [8,9]. Not all studies agree, though [10,11]. 
Also beta-blockers have been associated with a reduction in PCa risk [12]. In addition to studies 
estimating antihypertensive drugs as a group, captopril as a single drug may reduce the risk of 
prostate cancer [13]. Challenge for epidemiological studies on antihypertensive drugs is that it is 
common to simultaneously use several different antihypertensive drugs, especially among the 
elderly.  Therefore, when studying the independent effect of one drug or drug group, it is 
imperative to take into account simultaneous use of other drugs for the same indication.  Here, we 
evaluated prostate cancer survival and risk of starting androgen-deprivation therapy after radical 
prostatectomy by anti-HT drug use in a nationally comprehensive cohort while taking into account 
simultaneous use of multiple drug groups. Our pre-specified hypothesis was that use  
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of ACE-inhibitors, ATR blockers, beta-blockers and calcium-channel blockers might be associated 
with better survival. 
3 MATERIALS AND METHODS 
Study cohort 
Our study cohort consisted of 14,422 men with prostate cancer who were treated with radical 
prostatectomy in Finland during years 1995-2013. The cases were identified from the Finnish 
Cancer Registry, which covers approximately 95 % of cases diagnosed yearly in Finland. 
Information in the registry is gathered via mandatory reports of all cancer diagnoses made in 
Finnish health care units.[14] The Registry collects data on the primary site of cancer, histology, 
date and method of diagnosis, primary treatment method and date and cause of death. Limited 
information on tumor extent is also available. The registry does not record Gleason score or PSA 
level at diagnosis. 
Information on antihypertensive medication use 
The study cohort was linked to a national prescription database for comprehensive information on 
antihypertensive drug use during 1995-2013. The linkage was done using unique personal 
identification number. The national prescription database is maintained by the Finnish Social 
Insurance Institution (SII). SII provides reimbursements for physician-prescribed drug purchases to 
all Finnish citizen as part of the national health insurance. Reimbursements are available for all 
purchases of SII-approved drugs in an outpatient setting. Drugs administered during inpatient 
periods are not recorded in the database.  The information on each purchase includes dose, the 
date, package size and number of packages bought.  
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All purchases of anti-HT drugs were identified using drug-specific ATC-codes (Supplementary table 
1). Antihypertensive drugs were categorized into six separate drug groups: Angiotensin converting 
enzyme (ACE) -inhibitors, Angiotensin-receptor blockers (ATR-blockers), diuretics, beta-blockers, 
calcium-channel blockers and other antihypertensive drugs. The diuretics group includes thiazides, 
loop-diuretics and potassium-sparing diuretics.  The Angiotensin-receptor blocker group includes 
drugs blocking the AT1 receptor, a receptor for angiotensin 2.  
In addition to anti-HT drugs, information on use of statins was also collected from database as they 
are often used simultaneously with anti-HT medication. No information on use of other drugs than 
statins and anti-HT drugs was collected. 
Information on androgen deprivation therapy 
Information on purchases of GnRH-agonists and -antagonists and antiandrogens were obtained 
from the prescription database, identified by drug-specific ATC-codes (Supplementary table 1). 
The cohort was linked to Care Registry (HILMO) maintained by the National Institute For Health 
And Welfare to collect information on orchiectomies (Nordic Classification of Procedures code 
KFC00) conducted in study population during 1995-2013. The Registry records all diagnoses and 
medical procedures from in- and outpatient hospital visits in Finland.  
 Information on orchiectomies was combined to information on use of GnRH-agonists and -
antagonists and antiandrogens to identify men starting androgen deprivation therapy (ADT) after 
radical prostatectomy. Combined information was used as a proxy for disease recurrence after 
prostatectomy.  
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Diagnoses recorded in the HILMO database were also used to calculate Charlson co-morbidity 
index [15] for each participant. Conditions used in the index calculation are listed in 
Supplementary table 2. 
Statistical analysis 
Separate analyses were performed for drug usage before and after PCa diagnosis. We compared 
risk of prostate cancer death between users and non-users of anti-HT drugs. 
The total yearly mg amount of purchases of each anti-HT drug was calculated for each participant 
based on the dosing, number of packages and package sizes from each purchase. Then, the 
purchased yearly mg amount was divided with the dose corresponding to drug-specific Defined 
Daily Dose (DDD) [16] for the total number of DDDs the person had purchased per year. Each year 
with recorded medication purchases was considered as year of usage regardless of the purchased 
amount. 
Cumulative number of DDDs and years of usage were calculated separately for each year after PCa 
diagnosis. Yearly dosing was evaluated by forming an intensity variable dividing cumulative 
number of DDDs with cumulative number of years of usage. Anti-HT medication use before PCa 
diagnosis was estimated by adding together usage from all years between 1995 and the year of 
the diagnosis. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence 
intervals (95% CIs) for the risk of prostate cancer death and for starting ADT after diagnosis. Time 
metric was years and months since PCa diagnosis. In analyses for the risk of death the follow-up 
continued until death, emigration or the common closing date Dec 31, 2013, whichever came first. 
In analyses for the risk of starting ADT after diagnosis the follow-up continued until first record of  
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any ADT (medical or surgical castration, antiandrogen use), death or the common closing date. Cox  
regression analyses were adjusted for age at diagnosis, tumor extent (categorized as local, locally 
advanced, metastatic or unknown), Charlson co-morbidity Charlson co-morbidity index and use of 
statins during the follow-up.  Sensitivity analyses were stratified by time of PCa diagnosis (1995-
1999, 2000-2009, 2010 or later) to estimate role of changed criteria for operative management in 
the risk association by anti-HT drug use over the course of time. 
Anti-HT drug use before diagnosis was analyzed as time-fixed variable taking into account the 
duration and cumulative dose of use occurring between 1995 and year of PCa diagnosis. Post-
diagnostic use was analyzed as time-dependent variable to minimize immortal time bias. Time-
dependent variables were formed by updating medication user status as well as cumulative 
amount, duration and intensity of use separately for each follow-up year after PCa diagnosis. Dose 
dependence was evaluated by stratifying medication users by tertiles of DDD amount, duration 
and intensity of use based on the level reached on each follow-up year  
Simultaneous use of multiple anti-HT drug groups was modelled by forming separate time-
dependent variables for use of each drug group, i.e. ACE-inhibitors, ATR-blockers, beta-blockers, 
calcium channel blockers, diuretics and other anti-HT drugs not belonging to these groups. These 
variables were included in the Cox regression model simultaneously. Participants who had 
purchased more than one anti-HT drug group in a given year were considered as users for each 
drug group variable of which they had purchases.  
Long-term association between anti-HT drug use and risk of prostate cancer death was 
investigated in lag time analyses where the exposure was lagged forward in the follow-up time;  
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analyzing medication use that occurred one, three or five years before. 
The data was analysed using the IBM SPSS statistics 24 program. All reported p-values are two-
sided. 
4 RESULTS 
Population characteristics 
Anti-HT drug use was very common in our study population. Of the 14,422 men 9,799 (67.9%) had 
used at least one anti-HT drug before or after diagnosis; 4,625 (32.1%) men had not used any kind 
of anti-HT medication.  Compared to non-users, anti-HT medication users were older at diagnosis 
(median age 63 years), had more often localized tumor extent and also used more often statins 
and antidiabetic medication. During the median follow-up of 9.9 years after PCa diagnosis, a total 
of 1,581 men (11/100 men) died. Of these, 424 (3/100) died of PCa (Table 1). Ten year overall 
mortality was 7.5/100 men. A total of 2,849 men (20/100 men) started androgen deprivation 
therapy during the follow-up. 
Antihypertensive drug usage before prostate cancer diagnosis 
Compared to non-users, men who had used ATR- blockers before the diagnosis had a lower risk for 
prostate cancer death both in the age-adjusted and multivariable adjusted analysis (multivariable 
adjusted HR: 0.43 CI: 0.26-0.72) (Table 2). When stratified by duration of use also the other anti-
HT drug groups, such as ACE inhibitors, calcium channel blockers and beta blockers were 
associated with lowered risk of PCa death in some strata. However, when stratified by average 
yearly dose of usage the decreased risk was observed only at low-dose use for drug groups other 
than ATR-blockers (Table 2). In users of ATR-blockers the risk decrease was observed regardless of  
11 
yearly dosage.  
In contrast, usage of diuretics before the diagnosis was associated with borderline significant 
increase in risk of PCa death (HR 1.62, 95% CI 0.97-2.70). When stratified by cumulative use, the 
risk increase was observed only in the strata of lowest cumulative amount ( HR: 1.67 CI: 1.10-
2.54), but not in longer-term or high-dose use.   
Antihypertensive drug use after the diagnosis 
Post-diagnosis use of ATR- blockers was associated with better prostate cancer survival compared 
to non-users both in the age-adjusted and multivariable-adjusted analyses (Table 3). The risk 
decrease persisted even with five years’ lag time.  
In contrast, use of any other antihypertensive drugs was associated with an increased risk 
compared to non-users (Table 3). When drug groups were analyzed separately, the risk increase 
was significant only for post-diagnosis use of beta-blockers. The increased risk estimates 
attenuated within five years’ lag-time, but remained elevated compared to non-users for beta-
blockers and ACE inhibitors. 
Dose-dependence of the risk association between ATR- blocker use and prostate cancer death 
The risk of PCa death decreased in inverse association with average annual dose of ATR-blocker 
use post-diagnosis, although the stratified risk estimates were non-significant (Table 4).   For ATR-
blocker use before PCa diagnosis no clear dose-dependence in the risk association was observed. 
Anti-HT drug use and risk of starting androgen deprivation therapy (ADT) 
Pre-diagnostic use of most anti-HT drug groups was associated with elevated risk of starting ADT  
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after prostatectomy compared to non-users (Table 5). Only exception was ATR-blockers, which  
were associated with a reduced risk of starting ADT (HR: 0.81 CI: 0.71-0.92). 
For post-diagnostic use, ATR-blockers remained to be associated with lowered risk of starting ADT 
(HR: 0.80 CI: 0.69-0.92) (Table 5). However, no significant risk difference was observed between 
users and non-users of other groups of anti-HT drugs. 
 
Sensitivity analyses 
When analyzing all cause mortality a decreased risk among users of ATR-blockers ( HR: 0.73, CI: 
0.58-0.92) and increased risk among users of all other anti-HT drug types was observed.  
To test whether the risk decrease observed in ATR-blocker users was only due to telmisartan, we 
re-ran the analysis after exclusion of telmisartan users. ATR blocker use remained associated with 
lowered risk of PCa death (HR 0.50, 95% CI 0.28-0.88). 
We also tested whether captopril had differing risk association compared to ATR-blockers. After 
excluding captopril the risk of PCa death was lowered in ATR-blocker users compared to non-users 
(HR: 0.35 CI: 0.21-0.57). Captopril alone was associated with increased risk of PCa death (HR: 2.09 
CI: 0.67-6.58).  
After excluding use of all other anti-HT drugs except ATR-blockers the risk decrease wasn´t 
statistically significant but stayed decreased (HR: 0.64 CI: 0.09-4.65). 
To test effect of ATR-blockers on PCa survival in different time periods we divided our data in 
three groups based on year of diagnosis: 1995-1999, 2000-2009 and 2010-2014. We re-run the  
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analyses in those three groups. The risk decrease among ATR-blockers was observed only in group 
1995-1999 but not in other groups. The risk associations weren´t statistically significant as the 
number of PCa deaths was low. Risk estimates for ATR-blockers in group 1995-1999 (HR: 0.246 CI: 
0.034-1.788), in group 2000-2009 (HR: 1.018 CI:0.588-1.762) and in group 2010-2013 ( HR: 1.772 
CI: 0.134-23.479).  
We also tested if year of diagnosis affected the results. Operative management is conducted soon 
after diagnosis and we supposed that year of surgery was the same as the year of diagnosis. We 
added year of PCa diagnosis in our multivariable analyses before and after PCa diagnosis. The risk 
decrease among ATR-blockers became statistically non-significant in pre-diagnostic analyses (Table 
6). The decreasing effect of diuretics and beta-blockers on PCa survival increased (Supplementary 
table 3 and 4). In analyses before PCa diagnosis some changes in risk estimates were observed but 
at non-significant level (Table 7). 
5 DISCUSSION 
In our study antihypertensive drugs are generally associated with increased risk of PCa progression 
after radical prostatectomy as measured by starting ADT use and prostate cancer death. The risk 
association was observed for multiple anti-HT drug groups with distinctly different mechanisms of 
action, like beta-blockers and diuretics. This suggests that the risk increase is caused by underlying 
common indication for medication use, i.e. hypertension. The risk association was strongest when 
anti-HT medication use had started before PCa diagnosis, suggesting that hypertensions may be a 
risk factor for PCa progression in long-term. 
In contrast, use of ATR- blockers was associated with lowered risk of starting ADT and improved  
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prostate cancer survival. The risk decrease was significant both for usage before and after PCa  
diagnosis.  No clear dose-dependence was observed for usage before PCa diagnosis, but for post-
diagnostic use the risk of PCa death decreased in inverse correlation with the intensity, cumulative 
amount and years of ATR-blocker use. The differing risk association as compared to other anti-HT 
drugs and the dose-dependent risk association support causal association between ATR-blocker 
use and PCa prognosis. The risk of starting ADT after prostatectomy was high also among ATR-
blocker users which argues against selection bias of more favorable risk cases among them. 
However, also non-causal explanations should be considered.   
In subgroup analyses where we analyzed the effect of year of diagnosis the risk decrease among 
ATR-blockers remained decreased. Because of low numbers of PCa deaths the risk decrease was 
observed only in cases diagnosed in the 90s and which therefore have had sufficient time to reach 
any significant PCa mortality. There may be selection bias among ATR-blocker users that cause the 
difference between ATR-users and other anti-HT users. ATR-blocker users may be healthier as we 
don´t have information on therapeutic equilibrium of other diseases. However there are no 
differences in comorbidity indexes or risk of starting ADT between ATR-users and non-users.  
ACE inhibitors and ATR-blockers both affect renin-angiotensin-aldosterone system (RAA-system), 
lowering blood pressure. In addition, RAA-system also controls vascular growth by inhibiting  cell 
proliferation and mitosis via AT1 receptor [17]. However, our results do not directly support 
importance of RAA system in PCa progression as the risk decrease was observed only for users of 
ATR-blockers, whereas ACE inhibitors were associated even with an increased risk of PCa death. 
Thus, the specific mechanism of how ATR-blockers may decrease the risk of PCa death and reduce  
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disease recurrence remains unclear. In vitro, telmisartan but not other sartans has been reported  
to cause apoptosis in prostate cancer cells [18]. However, in sensitivity analyses the survival 
benefit among ATR-blocker users compared to non-users remained after exclusion of telmisartan 
users, confirming that the risk decrease is observed for ATR blockers as a group. Further studies 
are needed to elucidate the possible mechanism for the risk decrease only among ATR-blocker 
users. 
All anti-HT drugs except beta-blockers are the first line treatment of hypertension in Finland. Beta-
blockers are used to treat hypertension combined with coronary artery disease. It is also possible 
that men using ATR-blockers are systematically different from men using other types of anti-HT 
drugs, which may cause selection bias to cause the difference compared to other anti-HT drug 
groups. Nevertheless, selection bias should not be dose-dependent, whereas in our study a dose-
dependent inverse risk association between ATR-blocker use and PCa death was observed. This 
argues against selection bias. Further, all men had been treated with radical prostatectomy at 
baseline, which presumably makes the study population fairly homogenous. Concordantly, the 
distribution of measured background characteristics were similar in men using ATR-blockers and 
those using other types of anti-HT drugs. 
The strengths of our study are long follow up -time, detailed information on timing and amount of 
medication use and a nationwide study cohort, covering all PCa patients managed with 
prostatectomy in Finland since 1995. We were able to take into account use of other drugs and 
analyze separately each anti-HT drug group. Our registry-based data on medication use was 
exceptionally detailed and free of recall bias. 
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The main limitation of the study is low number of PCa deaths in this cohort of operatively 
managed PCa patients. This limited statistical power in subgroups analyses.  We did not have 
information on therapeutic equilibrium of the participants’ hypertension and we cannot be sure if 
anti-HT drugs were used to control other diseases than hypertension. Beta-blockers and diuretics 
are also used to treat coronary artery disease which has been suggested as PCa risk factor [19,20]. 
Our data on medication use was based on recorded medication purchases, we had no information 
whether the drugs were actually consumed. Further, we had no information on life-style factors 
such as BMI, smoking, diet or exercise activity which could have served as confounding factors. 
However, role of these conditions as risk factors for PCa progression or death is unclear.  
In conclusion, antihypertensive drugs are associated with increased risk of PCa death and starting 
of ADT after radical prostatectomy. An exception are ATR-blockers which are associated with 
better PCa survival and lowered risk of starting ADT. The risk decrease is observed in inverse 
association with annual dose of ATR-blocker use. Our results support further studies elucidating 
the mechanism behind the possible anticancer effect, and ultimately doing clinical trials testing 
ATR-blockers in men with prostate cancer. 
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7 TABLES 
Table 1. Population characteristics. 
 
 non-users ACE-
inhibitors 
ATR-
blockers 
beta-
blockers 
calcium-
channel 
blockers 
diuretics other 
anti-HT 
drugs 
n of men 4624 5045 4153 6367 4806 5016 410 
median 
follow time 
(IQR) 
8.08 (5.4-
11.6) 
10.6 (6.7-
14.0) 
10 (6.4-
13.6) 
10.4 ( 6.7-
14.2) 
10.3 (6.6-
14.0) 
10.5 (6.8-
14.1) 
11.1 (7.3-
14.9) 
n of Pca 
deaths (% 
of users) 
85 (1.8%) 131(2.6%)  77 (1.9%) 207 (3.3%) 133 (2.8%) 247 (4.9%) 16 (3.9%) 
n (%) of 
starting 
ADT 
729 
(15.8) 
1089(21.6) 792 (19.1) 1439 
(22.6) 
1055 
(22.0) 
1239 (24.7) 107 
(26.1) 
Charlson 
comorbidity  
index , 
median 
(IQR) 
2 (2-4) 2 (2-6)  2 (2-6) 2 (2-6) 2 (2-6) 2 (2-6) 2 (2-4) 
Age at 
diagnosis, 
median 
(IQR) 
61 (33-
91) 
63 (40-
93)* 
62 (40-93) 63 (39-
92)* 
63 (40-
88)* 
63  (40-93)* 63 (42-
87) 
Tumor extent at diagnosis, n( %)      
Localized 3252 
(70.3) 
3626 
(71.9)* 
3028 
(72.9)* 
4547 
(71.4)* 
3447 
(71.7)* 
3604 
(71.8)* 
299 
(72.9) 
Locally 
advanced 
851 
(18.4) 
779 (15.4) 637 (15.3) 989 (15.5) 756 (15.7) 779 (15.5) 57 (13.9) 
Unknown 522 
(11.3) 
640 (12.7) 488 (11.8) 831 (13.1) 603 (12.5) 634(12.6) 54 (13.2) 
Statin use, 
n (%) 
1274 
(27.5)  
3390 
(67.2)* 
2618 
(63.0)* 
4164 
(65.4)* 
3034 
(63.1)* 
3161 
(63.0)* 
269 
(65.6)* 
Antidiabetic 
medication 
use; n (%) 
279 (6.0) 1370 
(27.2)* 
1038 
(25.0)* 
1453 
(22.8)* 
1227 
(25.5)* 
1328(26.5)* 125 
(30.5)* 
 
* P < 0.05 for difference compared to non-users 
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Table 2. Risk of prostate cancer death by antihypertensive drug use before prostate cancer diagnosis. 
 
  Risk of PCa death 
Drug group n of users/PCa 
deaths 
HR (95% CI)age-
adjusted 
HR (95% 
CI)multiavariable adjusted* 
ACE inhibitors 530 / 28 1.02 (0.66-1.57) 1.10 (0.70-1.72) 
ATR-blockers 1781 / 15 0.39 (0.23-0.65) 0.43 (0.26-0.72) 
Average yearly 
dose of ATR-
blocker (mg/yr) 
   
0-286.22  592 / 5 0.34 (0.14-0.81) 0.38 (0.16-0.92) 
 286.22-460.00  596 / 6 0.43 (0.19-0.95) 0.50 (0.22-1.11) 
460→ 593 / 4 0.40 (0.15-1.09) 0.48 (0.18-1.28) 
beta-blocker 670 / 43 1.54 (1.01-2.14) 1.82 (1.30-2.56) 
calcium-channel 
blocker 
448 / 17 0.77 (0.47-1.27) 0.84 (0.51-1.40) 
diuretics 319 / 22 1.48 (0.89-2.45) 1.62 (0.97-2.70) 
other anti-HT 
drugs 
27 / 5 3.03 (1.24-7.43) 3.90 (1.59-9.62) 
 
*= calculated cox regression model with adjustments of age, tumor extent, CCI and statin use  
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 Table 3. Risk of prostate cancer death by antihypertensive drug use after prostate cancer diagnosis. 
 
  Risk of PCa death Lag-time 
Drug group n of users/PCa 
deaths 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multiavariable 
adjusted* 
1yr 3yrs 5yrs 
ACE inhibitors 4515/103 1.16 (0.85-
1.58) 
1.10 (0.81-
1.49) 
1.14 
(0.84-
1.56) 
1.14 
(0.83-
1.56) 
1.40(1.00 
-1.95) 
ATR blockers 2372/62 0.59 (0.36-
1.00) 
0.60 (0.37-
0.97) 
0.55 
(0.34-
0.89) 
0.52 
(0.31-
0.86) 
0.55 
(0.30-
0.98) 
Beta-blockers 5697/164 1.37(1.07-
1.75) 
1.30 (1.01-
1.67) 
1.43 
(1.11-
1.84) 
1.40(1.08-
1.81) 
1.30(0.98-
1.73) 
Calcium-channel 
blockers 
4358/116 1.04 (0.77-
1.40)  
1.01 (0.75-
1.37) 
1.02 
(0.75-
1.37) 
0.92 
(0.67-
1.26) 
0.97 
(0.69-
1.37) 
Diuretics 4698/225 1.30(0.93-
1.82) 
1.32 (0.95-
1.85) 
1.31 
(0.94-
1.84) 
1.14 
(0.80-
1.62) 
0.94 
(0.63-
1.40) 
Other 
antihypertensive 
drugs 
383/11 2.18(0.97-
4.91) 
1.89 (0.84-
4.26) 
1.96 
(0.87-
4.43) 
2.18(0.96-
4.92) 
2.34 
(0.96-
5.71) 
 
*= calculated cox regression model with adjustments of age, tumor extent, CCI and statin use 
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Table 4. Risk of prostate cancer death by cumulative amount, duration and average yearly dose of ATR- 
blocker use after diagnosis. 
 
Amount of use 
(mg) 
n of men/PCa 
deaths 
Riski of Pca death 
HR (95%CI) age-
adjusted 
Risk of Pca death 
HR (95% CI) 
multiavariable adjusted* 
0-1339.33 1351 / 36 1.13 (0.72-1.43) 1.13 (0.80-1.61) 
1339.33-4200.00 1392 / 30 0.85 (0.58-1.25) 0.91 (0.62-1.34) 
4200.00→ 1404 / 11 0.51 (0.25-1.05) 0.54 (0.26-1.10) 
 
Duration of use 
(years) 
n of men/PCa 
deaths 
Riski of Pca death 
HR (95%CI) age-
adjusted 
Risk of Pca death 
HR (95% CI) 
0-4  1547 / 44 0.84 (0.62-1.15) 0.91 (0.66-1.24) 
4-9  1367/ 24 0.61 (0.40-0.92) 0.64 (0.42-0.97) 
9→ 1239 / 9 0.03 (0.00-0.08) 0.02 (0.01-0.08) 
 
Average yearly 
dose (mg/yr) 
n of men/PCa 
deaths 
Riski of Pca death 
HR (95%CI) age-
adjusted 
Risk of Pca death 
HR (95% CI) 
0-310.33  1352 / 36 1.19 (0.83-1.67) 1.37 (0.96-1.97) 
310.33-536.27  1398 / 24 0.80 (0.52-1.23) 0.86 (0.56-1.33) 
536.27→  1403 / 17 0.60 (0.37-0.97) 0.61 (0.38-1.01) 
 
*= calculated cox regression model with adjustments of age, tumor extent, CCI and statin use  
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Table 5. Risk of starting androgen deprivation therapy (ADT) by antihypertensive drug use before or after 
prostate cancer diagnosis 
 
 Anti-HT drug use before diagnosis 
Drug group n of men starting ADT 
(%) 
HR (95% CI)age-adjusted HR (95% CI)multiavariable 
adjusted* 
ACE inhibitors 162 (30,6) 1.28 (1.08-1.53) 1.32 (1.11-1.58) 
ATR-blockers 250 (14,0) 0.81(0.71-0.93) 0.81 (0.71-0.92) 
Beta-blockers 211 (31,5) 1.33 (1.14-1.54) 1.38 (1.19-1.61) 
Calcium-channel 
blockers 
135 (30,1) 1.21 (1.01-1.45) 1.26 (1.05-1.51) 
Diuretics 89 (27,9) 0.89 (0.70-1.13) 0.90 (0.70-1.14) 
Other anti-HT drugs 13 (48,1) 1.91 (1.10-3.30) 2.24 (1.29-3.89) 
 Anti-HT drug use after diagnosis 
ACE inhibitors 1089 (24,1) 1.02 (1.03-1.05) 1.01 (0.90-1.13) 
ATR-blockers 792 (33,4) 0.80 (0.69-0.92) 0.80 (0.69-0.92) 
Beta-blockers 1439 (25,3) 1.11 (1.00-1.22) 1.09 (0.99-1.21) 
Calcium-channel 
blockers 
1055 (24,2) 1.06 (0.95-1.19) 1.05 (0.94-1.17) 
Diuretics 1239 (26,4) 0.99 (0.87-1.12) 1.00 (0.88-1.14) 
Other anti-HT drugs 107 (27,9) 1.43 (0.98-2.10) 1.44 (0.98-2.10) 
 
*= calculated cox regression model with adjustments of age, tumor extent, CCI and statin use 
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Table 6. Risk of prostate cancer death by antihypertensive drug use after prostate cancer diagnosis. 
Adjusted analyses with year of diagnosis. 
 
  Risk of PCa death Lag-time 
Drug group n of users/PCa 
deaths 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multiavariable 
adjusted (*) 
1yr 3yrs 5yrs 
ACE inhibitors 4515/103 1.16 (0.85-
1.58) 
1.28 (0.94-
1.74) 
1.23 
(0.91-
1.68) 
1.33 
(0.97-
1.82) 
1.45  
(1.03-
2.04) 
ATR blockers 2372/62 0.59 (0.36-
1.00) 
1.12 (0.68-
1.83) 
1.02 
(0.63-
1.68) 
1.03 
(0.62-
1.73) 
0.92 
(0.49-
1.69) 
Beta-blockers 5697/164 1.37(1.07-
1.75) 
1.39 (1.08-
1.79) 
1.34 
(1.04-
1.73) 
1.39 
(1.07-
1.80) 
1.32 
(0.99-
1.76) 
Calcium-channel 
blockers 
4358/116 1.04 (0.77-
1.40)  
1.04 (0.77-
1.40) 
1.01 
(0.75-
1.36) 
0.94 
(0.69-
1.29) 
1.00 
(0.71-
1.40) 
 Diuretics 4698/225 1.30(0.93-
1.82) 
1.30 (0.94-
1.82) 
1.29 
(0.92-
1.80) 
1.13 
(0.79-
1.61) 
0.99 
(0.67-
1.49) 
Other 
antihypertensive 
drugs 
383/11 2.18(0.97-
4.91) 
1.46 (0.65-
4.26) 
1.44 
(0.64-
3.26) 
1.69 
(0.75-
3.82) 
2.09 
(0.86-
5.09) 
 
*= calculated cox regression model with adjustments of age, tumor extent, CCI, statin use and year of PCa 
diagnosis 
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Table 7. Risk of prostate cancer death by antihypertensive drug use before prostate cancer diagnosis. 
Adjusted analyses with year of diagnosis.  
 
  Risk of PCa death 
Drug group n of users/PCa 
deaths 
HR (95% CI)age-
adjusted 
HR (95% 
CI)multiavariable adjusted* 
ACE inhibitors 530 / 28 1.02 (0.66-1.57) 1.20 (0.88-1.63) 
ATR-blockers 1781 / 15 0.39 (0.23-0.65) 0.96 (0.58-1.57) 
Average yearly 
dose of ATR-
blocker (mg/yr) 
   
0-286.22  592 / 5 0.34 (0.14-0.81) 0.66 (0.27-1.62) 
 286.22-460.00  596 / 6 0.43 (0.19-0.95) 0.99 (0.44-2.23) 
460→ 593 / 4 0.40 (0.15-1.09) 1.30 (0.48-3.54) 
beta-blocker 670 / 43 1.54 (1.01-2.14) 1.31 (1.02-1.68) 
calcium-channel 
blocker 
448 / 17 0.77 (0.47-1.27) 1.00 (0.74-1.34) 
diuretics 319 / 22 1.48 (0.89-2.45) 1.28 (0.92-1.79) 
other anti-HT 
drugs 
27 / 5 3.03 (1.24-7.43) 1.43 (0.63-3.225) 
 
*= calculated cox regression model with adjustments of age, tumor extent, CCI, statin use and year of PCa 
diagnosis 
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